| 1. |
- Dabaieh, Marwa, et al.
(författare)
-
ACCLIMATIZATION MEASURES FOR TEMPORARY REFUGEE SHELTERS IN HOT ARID CLIMATES; LOW-TECH MOBILE SOLUTIONS USING BEDOUIN TENTS
- 2015
-
Ingår i: [Host publication title missing]. - 9788894116311
-
Konferensbidrag (refereegranskat)abstract
- Global climate change has enormous impacts on urban areas in the developing world. The known and growing effects of climate change, like increased temperatures and increased incidence of severe storms, is evident. This winter, 2015, extreme cold waves and snow storms hit the Middle East region. Death rates in Syrian refugee camps were significant due to inefficient temporary shelters. Children and seniors were typically the most vulnerable. Additionally, the urban structures did not consider social needs and cultural behaviors. This paper investigates current social and environmental problems within Syrian refugee camps in Jordan, Egypt and Lebanon. The paper offers an analysis of Bedouin communities in the Middle East for possible use of Bedouin tents structures and clustering as a resilient solution for housing and shelter. The aim of this study is to understand the environmental behavior of the Bedouin tent structure together with socio-cultural implications among the Bedouin community. The paper applied an investigative and analytical approach using qualitative site survey methods. It concludes by defining thermal comfort adaptation measures and social clustering adopted by local Bedouin inhabitants inside their tents and draws an applicable and hands-on proposal for using such adaptation measures in current low-tech emergency shelters, especially for low-income refugees.
|
|
| 2. |
- Kamposioras, Konstantinos, et al.
(författare)
-
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies : How to Navigate Through Covid-19 Labyrinth
- 2020
-
Ingår i: Frontiers in Oncology. - : Frontiers. - 2234-943X. ; 10
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
|
|
| 3. |
- Mauri, Davide, et al.
(författare)
-
Behind the numbers and the panic of a viral pandemic : fixed restrictive oncology guidance may jeopardize patients' survival
- 2020
-
Ingår i: Balkan Union of Oncology. Journal. - : Zerbinis Publications. - 1107-0625. ; 25:3, s. 1277-1280
-
Tidskriftsartikel (refereegranskat)abstract
- To protect cancer patients from COVID-19 exposure, prioritization strategies are being implemented at global level. Measures include use of tele-health services, deferring elective surgeries, delaying non life-saving therapies, interrupting maintenance and supportive care regimens and suspending screening and regular follow-up visits.Nonetheless, the risk of infection may not always outweigh oncology treatment benefit. Lives of most oncology patients depend on their ability to receive medical, surgical and radiotherapy care. Postponing screening,follow-up and radical surgeries increase patients' risk of developing metastatic disease.A viral pandemic lasts long time and exhibits seasonal and geographical variations. Though vaccines will be available only in the 2021, a global, aggressive, all-embracing and protracted slowdown of oncologic activities will severely jeopardize patients' outcomes.A present international oncologists' panel, ECPC and FAVO, strongly suggest that Hospital measures in a specific geographical area/Nation should be in line with the local epidemic, and restrictions adopted should be adapted and stratified over time.
|
|
| 4. |
- Mauri, Davide, et al.
(författare)
-
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy : Time to Rethink Our Approach
- 2022
-
Ingår i: Oncology Research and Treatment. - : S. Karger. - 2296-5270 .- 2296-5262. ; 45:4, s. 216-220
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge.Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions.Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.
|
|
